Novel Strategies to Combat Bacterial Biofilms.
Fatemeh HemmatiMohammad Ahangarzadeh RezaeeSaba EbrahimzadehLeila YousefiRoghayeh NouriHossein Samadi KafilPourya GholizadehPublished in: Molecular biotechnology (2021)
Biofilms are considered as a severe problem in the treatment of bacterial infections; their development causes some noticeable resistance to antibacterial agents. Biofilms are responsible for at least two-thirds of all infections, displaying promoted resistance to classical antibiotic treatments. Therefore, finding new alternative therapeutic approaches is essential for the treatment and inhibition of biofilm-related infections. Therefore, this review aims to describe the potential therapeutic strategies that can inhibit bacterial biofilm development; these include the usage of antiadhesion agents, AMPs, bacteriophages, QSIs, aptamers, NPs and PNAs, which can prevent or eradicate the formation of biofilms. These antibiofilm agents represent a promising therapeutic target in the treatment of biofilm infections and development of a strong capability to interfere with different phases of the biofilm development, including adherence, polysaccharide intercellular adhesion (PIA), quorum sensing molecules and cell-to-cell connection, bacterial aggregation, planktonic bacteria killing and host-immune response modulation. In addition, these components, in combination with antibiotics, can lead to the development of some kind of powerful combined therapy against bacterial biofilm-related infections.
Keyphrases
- candida albicans
- pseudomonas aeruginosa
- staphylococcus aureus
- biofilm formation
- immune response
- single cell
- stem cells
- type diabetes
- risk assessment
- dendritic cells
- cell therapy
- early onset
- cystic fibrosis
- combination therapy
- metabolic syndrome
- inflammatory response
- toll like receptor
- escherichia coli
- mesenchymal stem cells
- smoking cessation
- glycemic control